Loading clinical trials...
Loading clinical trials...
This study is a retrospective analysis of an homogeneous population of patients with aggressive B-cell lymphoma and treated upfront with R-CHOP or R-CHOP like regimens to reassess the prognostic facto...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Fondazione Italiana Linfomi - ETS
NCT04488354 · Relapsed/Refractory B-cell Lymphomas, Diffuse Large B-Cell Lymphoma (DLBCL), and more
NCT05583149 · Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, and more
NCT02904577 · Indolent B-Cell Lymphomas
NCT01897571 · B-cell Lymphomas (Phase 1), Advanced Solid Tumors (Phase 1), and more
NCT01744912 · Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia, and more
Hemocentro-Unicamp
Campinas
Centro Medico
Santa Isabel
Centro Paulista de Oncologia
São Paulo
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions